TFF Pharmaceuticals Inc (NASDAQ:TFFP) has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for defensive research into countermeasures against biological warfare.
- Under the terms of the CRADA, TFF Pharma and USAMRIID will evaluate the immune response of a dry powder recombinant Vesicular Stomatitis Virus Severe Acute Respiratory Syndrome Coronavirus-2 Glycoprotein (TFFD-rVSV-SARS2-GP) vaccine formulated using TFF's Thin Film Freezing technology.
- USAMRIID will assess the immunogenicity and protective efficacy of inhaled dry powder formulation against SARS-CoV-2 induced in an animal model compared to the intramuscular administration.
- Related: TFF Pharma's Inhaled Niclosamide Shows Potent Activity Against Omicron Variant.
- Earlier in 2021, under the existing CRADA, TFF Pharmaceuticals announced positive preclinical data showing the two Thin Film Freezing-formulated biodefense countermeasures maintained efficacy in an in vitro viral neutralization assay.
- TFF Pharmaceuticals' Thin Film Freezing (TFF) platform is designed to improve the solubility and absorption of poorly water-soluble drugs. It is particularly suited to generate dry powder particles with properties targeted for inhalation delivery.
- Price Action: TFFP shares are up 9.32% at $6.57 during the market session on the last check Thursday.
